The successful induction of a T-cell-mediated tumor-protective immunity against poorly immunogenic malignancies remains a major challenge for cancer immunotherapy. We 
Introduction
The induction of an effective systemic protective immunity against malignancies is a major objective for cancer immunotherapy. The goal is to break peripheral tolerance of the immune system towards poorly immunogenic tumors by activating cytotoxic T -cells (CTL) and/or natural killer (NK) cells to effectively eradicate disseminated tumor metastases. In the field of DNA-vaccination, it has been shown by others and ourselves [1] [2] [3] that this can be achieved in melanoma with vaccines encoding TRP1, TRP2 and gp100 antigens 4 and in colon carcinoma with the CEA antigen [5] [6] [7] . In this regard, it has been reported that autoreactive T-cells which escape negative selection in the thymus can be activated in the periphery 8 to be directed against the tumor, resulting in an efficient tumor-protective immune response. Importantly, there is also evidence that aside from T-cells, the innate immune system plays a role in the host's defense against neuroblastoma via NK cells, in particular if interleukin 2 (IL-2) is included in the therapy protocol. In fact, eradication of murine neuroblastoma metastases by a recombinant human/mouse chimeric anti-ganglioside GD2-IL-2 fusion protein (ch14.18IL-2) was entirely NK-cell dependent when administered in therapeutic doses 9 .Moreover, once neuroblastoma patients were treated with IL-2 transduced autologous neuroblastoma tumor cells, they presented with an increase in activated T-cells and NK-cells, indicating a role for both effector populations in IL-2 immunotherapy of this malignancy 10 . We also recently reported that a mouse mTH-based DNA vaccine elicits an anti-tumor effect in a poorly immunogenic murine model of neuroblastoma 11 . However, therapy with this DNA vaccine containing solely the tumor associated antigen mTH was of limited efficacy as indicated by only a partial reduction in s.c. tumor growth. Therefore we tested the For personal use only. on November 12, 2017 . by guest www.bloodjournal.org From hypothesis that the PRE sequence of the woodchuck hepatitis virus (WPRE), in conjunction with mTH as a target antigen, could improve the systemic tumor-protective immune response against neuroblastoma metastases and provide complete tumor protection. The rationale for this approach is based on the observation that human hepatitis B virus (HBV) and woodchuck hepatitis B virus (W-HBV) contain posttranscriptional-acting RNA elements (PRE) that significantly enhance viral gene expression; however, woodchuck PRE sequences enhance gene expression to a greater extent than their equivalents of the human hepatitis B virus 12 . In fact, its WPRE sequence acts independent of transcription and splicing and thus may improve gene expression by modification of polyadenylation, RNA export or translation [13] [14] . Moreover, recent in vitro studies demonstrated gene expression of human multidrug resistance 1 (MDR1) and enhanced green fluorescent protein (EGFP) genes to be enhanced by post-transcriptional modification with the WPRE sequence 15 . In addition, Popa et al suggested that WPRE is directing messages into a CRM1-dependent mRNA export pathway in somatic mammalian cells 16 . These observations raised the question whether this event could also occur in vivo and be used to optimize the mTH-based DNA vaccine.
Interleukin 2 (IL-2), a well known, strong promoter of T-cell proliferation, which at low levels induces T-cell expansion 17; 18 , provides the rationale for boosting an initial immune response provoked by the mTHWPRE vaccine with the recombinant antibody-IL-2 fusion protein ch14.18-IL-2. This fusion protein uses disialoganglioside GD2 (GD2) as a docking site on neuroblastoma cells, where it is overexpressed and was already successfully used as a target for immunotherapy in neuroblastoma patients [19] [20] [21] and For personal use only. on November 12, 2017 . by guest www.bloodjournal.org From mouse models of this malignancy as well as other GD2 expressing tumors [22] [23] . In fact, IL-2 directed to the tumor microenvironment could locally amplify and expand an initial immune response provoked by the mTH-WPRE vaccine.
Here, we demonstrate for the first time, that post-transcriptional modification of an antitumor DNA vaccine with the WPRE sequence results in an enhanced immune response that in combination with the ch14.18-IL-2 fusion protein leads to complete T-cell and NK-cell-mediated protection from neuroblastoma metastases.
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Materials and methods

Construction and characterization of DNA vaccines encoding mTH and WPRE
The coding sequence for mTH was generated from the pCMV 3FUB plasmid encoding for mTH as described earlier 11 
Generation and characterization of tumor-specific antibody-IL-2 fusion protein
The ch14.18-IL-2 fusion protein was constructed by fusion of a synthetic sequence coding for human IL-2 to the carboxyl terminal of the human C 1 gene of the mouse human chimeric anti-GD2 antibody ch14.18 essentially as described previously 24 .
Neuroblastoma tumor model and treatment protocol
Syngenic female A/J mice were obtained at 8- 
Flow cytometry
Staining for expression of cell surface antigens and intracellular antigens was performed as described previously 25 . Splenocytes of control mice and immunized mice were isolated as described for the cytotoxicity assay and stimulated for 5 hours with 5 ng/ml PMA (Sigma, St. Louis, MO) and 500 ng/ml ionomycin (Sigma). All stimulated cultures contained 1µg/ml Brefeldin A (Sigma) to block protein transport into post-Golgi compartments and to allow cytokines to accumulate within cells. Cells were analyzed on a FACS Scan flow cytometer using Cell Quest software.
Statistics
The statistical significance of differential findings between experimental groups of animals was determined by the two-tailed Student's t-test. Findings were regarded as significant if two-tailed p values were <0.05.
For personal use only. on November 12, 2017. by guest www.bloodjournal.org From
Results
Effect of WPRE-enhanced DNA vaccine on in vitro expression of mTH antigen
The post-transcriptional regulatory PRE element of the woodchuck hepatitis virus was cloned and inserted as described in Material and Methods, directly downstream of the tumor-associated mTH antigen and following the stop codon. The correct sizes of the mTH and the WPRE fragments were analyzed by restriction enzyme digestion with a 1497bp fragment encoding for mTH and a 641bp fragment for the WPRE sequence 5 NXS2 wild-type tumor cells one week after the second immunization and boosted 2 days thereafter with 10µg ch14.18-IL-2 for 4 consecutive days. Mice were sacrificed 4 weeks after tumor cell challenge and hepatic metastases were assessed by liver weight in mg and counting of individual metastatic foci. Differences in liver weights of mice, that received the combination therapy, mTH-WPRE vaccination and ch14-18-IL-2 boost were statistically significant ( p=0.028, p=0.02) as compared to the groups of mice, that received either mTH plus boosts with the ch14.18-IL-2 or mice that were immunized with the mTH-WPRE vaccine alone. Tumor-specific cytotoxic activity, determined by a standard 51 Cr-release assay with splenocytes isolated from mice of each experimental group indicated that only animals immunized with the mTH-WPRE DNA vaccine plus ch14.18-IL-2 boosts produced a 3-fold increase in specific cytolysis of NXS2 tumor target cells over controls ( Figure 5 ).
This finding indicates that a tumor specific CTL response requires this combined treatment regimen since neither of these components alone could induce increased tumor-specific cytotoxic activity. Cr-release assay for splenocytes of mice immunized with either pcDNA3.1mTH (o); boosted with the ch14.18-IL-2 fusion protein in addition to mTH-vaccination ( ); WPREenhanced mTH vaccine, pcDNA3.1mTHWPRE ( ); and a combination therapy of mTHWPRE vaccination plus ch14.18-IL-2 fusion protein boost ( ). Results were compared to controls either immunized with the empty vector ( ) or treated with the ch14.18-IL-2 fusion protein alone ( ) Significantly, previous experiments demonstrated, that once the ch14.18-IL-2 fusion protein was administered in therapeutic dosages, the eradication of neuroblastoma metastases was entirely NK-cells dependent 9 . This finding lead to the assumption that besides CD8 + T-cells, the innate immune system may be activated by the mTH-WPRE DNA vaccine, especially following boosts with the ch14.18-IL-2 fusion protein.
Therefore, we investigated the role of NK-cells in a second set of experiments where all A/J mice in the experimental groups were depleted of NK-cells in vivo with anti-asialo GM1 anti-serum (Table 1) . In this case, systemic protective immunity against NXS2
wild-type tumor cells was completely abrogated in all treatment groups in contrast to non-depleted controls, indicating that NK-cells expressing GM1 play a crucial role in the mediation of systemic tumor-protective immunity in our model system.
For Mice were treated by oral vaccination with 1x10 8 Salmonella, containing pcDNA3.1; pcDNA3.1mTH; pcDNA3.1mTH-WPRE on day 0 (prime) and day 14 (boost), challenged with 5 x10 5 NXS2 wild-type tumor cells on day 21 and treated with 10 µg ch14.18-IL-2 two days thereafter for 4 consecutive days. Mice (n=4) were sacrificed 28 days after tumor cell challenge and metastases to the liver assessed. NK-cell depletion was performed with injection of 100 ml anti-asialo GM1 weekly for 4 weeks, starting one day prior to tumor cell challenge. Differences in liver weights between mice of all experimental groups depleted with anti-asialo GM1 as compared to non-depleted mice were statistically significant (p< 0
Discussion
In order for immunotherapy to achieve long-term remission in cancer patients with minimal residual disease, it is crucial to break peripheral tolerance against tumor selfantigens. This remains the goal of immunotherapy regimens designed to achieve tumor-protective immunity. Here, we tested the hypothesis that systemic tumorprotective immunity can be induced by a DNA vaccine, which was post-transcriptionally In contrast, the mTH vector alone could not induce full protection which was in accordance with our previous results
11
. Interestingly, although we were unable to detect an enhancement of mTH expression by addition of WPRE in vitro , our in vivo data clearly indicate that immunization with the WPRE-enhanced vaccine leads to significantly improved tumor-protective immunity. However, the mechanisms involved in the enhanced induction of protective immunity by the WPRE element are not entirely understood. Recent reports revealed some mechanistic features of post-transcriptional elements which affect RNA metabolism at the level of RNA-stability, polyadenylation, and nucleo-cytoplasmic transport 13-15; 26-27 . Remarkably, besides these quantitative 
